We investigated the effectiveness of nicotinamide, the active form of vitamin B3, in reducing skin cancers, particularly non-melanoma skin cancers (NMSCs). Our exploration included a systematic review of available literature, analyzing data from studies that assessed the potential benefits of oral nicotinamide among high-risk patients, including those with compromised immune systems.
After sifting through 225 studies, we found only four met our criteria for inclusion. The results were clear: there was no significant association between nicotinamide intake and a reduced risk of squamous cell carcinoma (SCC) or basal cell carcinoma (BCC). The statistics showed a rate ratio for SCC at 0.81 and for BCC at 0.88, which indicates no substantial benefit.
Although adverse effects from nicotinamide treatment were rare and manageable, the evidence points towards an insufficient impact of oral nicotinamide therapy on reducing keratinocyte cancers. It’s important to communicate that, while our findings are thorough, they highlight the need for more research. Overall, the use of dietary niacin intake also showed only a potential benefit related to SCC, but no effect on BCC or melanoma.
Read More